Stocks · News reference

Canaccord Genuity Raises Price Target for Aclaris Therapeutics

2026-10-31 13:03:53 UTC

Canaccord Genuity has maintained its 'Buy' rating on Aclaris Therapeutics and increased its price target from $10 to $13.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

Fiscal.ai2026-11-05 14:03:43 UTC
Aclaris Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate and Clinical Update
Aclaris Therapeutics announced its Q3 2026 financial results and provided updates on its clinical pipeline, including progress on Modzatinib, Bosakitug, and ATI-052.
ACRS
SEC EDGAR2026-11-05 12:15:22 UTCSEC EDGAR
8-K filing — Aclaris Therapeutics, Inc. (ACRS)
Filed: 2026-11-05 AccNo: 0001104659-26-123039 Size: 372 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
ACRS
Benzinga2026-10-31 00:27:07 UTCBenzinga Newsdesk
Canaccord Genuity Maintains Buy on Aclaris Therapeutics, Raises Price Target to $13
ACRS
Fiscal.ai2026-10-29 13:03:02 UTC
Wedbush Adjusts Aclaris Therapeutics Price Target to $8
Wedbush has lowered its price target for Aclaris Therapeutics from $10 to $8 while maintaining an Outperform rating.
ACRS
Benzinga2026-10-27 18:05:16 UTCVandana Singh
Aclaris Says Early Data Validates Dual-Target Approach for Eczema, Asthma Drug
Aclaris Therapeutics announces positive Phase 1b trial data for ATI-052 in eczema and asthma alongside a $50 million public financing round.
ACRS
Fiscal.ai2026-10-27 13:02:56 UTC
Aclaris Therapeutics Prices $50 Million Public Offering
Aclaris Therapeutics announced the pricing of an underwritten public offering of common stock and pre-funded warrants expected to generate approximately $50 million in gross proceeds.
ACRS